ESPs containing Sight Diagnostics
The ESP matrix leverages data and analyst insight to identify and rank leading companies in a given technology landscape.
Point-of-care (POC) testing refers to diagnostic lab tests that can be performed rapidly, reliably, and easily at or near the point of care. Starting with a biological sample, POC tests detect or quantify certain analytes ‚Äî such as infectious agents, cardiac markers, and blood glucose ‚Äî to inform clinical decision making.
Sight Diagnostics's Products & Differentiation
See Sight Diagnostics's products and how their products differentiate from alternatives and competitors
AI-based blood diagnostics analyzer that offers lab-grade Complete Blood Count (CBC) results from two drops of blood in minutes. OLO leverages a patented method of “digitizing” blood samples and is built with high-powered microscopes, computer vision, and artificial intelligence, allowing it to deliver lab-quality results in a much more compact and efficient format than traditional CBC machines. The analyzer’s computer vision technology produces over 1,000 highly detailed images of blood from each blood sample and then deploys fully automated AI algorithms to measure, classify, and count the different cells and identify abnormalities, measuring 19 different parameters with 5-part differentials, including full flagging capabilities.
When was Sight Diagnostics founded?
Sight Diagnostics was founded in 2011.
Where is Sight Diagnostics's headquarters?
Sight Diagnostics's headquarters is located at 23 Menahem Begin Street, Tel Aviv.
What is Sight Diagnostics's latest funding round?
Sight Diagnostics's latest funding round is Series D.
How much did Sight Diagnostics raise?
Sight Diagnostics raised a total of $127.52M.
Who are the investors of Sight Diagnostics?
Investors of Sight Diagnostics include OurCrowd, Longliv Ventures, Koch Disruptive Technologies, New Alliance Capital, Steven Esrick and 8 more.
Who are Sight Diagnostics's competitors?
Competitors of Sight Diagnostics include Visby Medical, OncoHost, Cardea Bio, Baebies, Oxford Immune Algorithmics, Noul, PixCell Medical Technologies, MeMed, Accellix, Inflammatix and 29 more.
What products does Sight Diagnostics offer?
Sight Diagnostics's products include Sight OLO.
You May Also Like
Truvian Sciences is a healthcare company at the intersection of diagnostics and consumer technology. Its automated benchtop system produces lab-accurate results for a full suite of health tests using a small sample of blood. Powered by patented technologies and intelligent integration, Truvian's system delivers an alternative to off-site labs, providing immediate insights to inform healthcare decisions.
BD is a medical technology company that manufactures and sells a broad range of supplies, devices, and systems for use by healthcare professionals, medical research institutions, industry, and the general public.
Cepheid is a molecular diagnostics company that develops, manufactures, and markets fully-integrated systems and tests for genetic analysis in the clinical, industrial, and biothreat markets. The company's systems enable rapid, sophisticated genetic testing for organisms and genetic-based diseases by automating otherwise complex manual laboratory procedures. The company's easy-to-use systems integrate a number of complicated and time-intensive steps, including sample preparation, DNA amplification, and detection, which enable the analysis of complex biological samples in its proprietary test cartridges. Through its strong molecular biology capabilities, the company is focusing on those applications where rapid molecular testing is particularly important, such as identifying infectious disease and cancer in the clinical market; food, agricultural, and environmental testing in the industrial market; and identifying bio-terrorism agents in the biothreat market. Cepheid previously traded under the ticker NASDAQ: CPHD.
MeMed is a med-tech and bio-convergence firm that researches, develops, and commercializes diagnostic host immune response testing methods that address complex clinical dilemmas and improve patient outcomes.
DiaSorin is a multinational biotechnology company that produces and markets in vitro diagnostics reagent kits used in immunodiagnostics and molecular diagnostics. It is based in Saluggia, Italy.
Baebies developed a nimble bioassay automation platform to rapidly perform multiplex enzymatic assays and other tests. The company licensed its core technology, digital microfluidics, from Illumina. In addition to a technology license in newborn screening that does not include sequencing, Baebies also received equipment, contracts, and other consideration in exchange for a share of ownership in the new company. The company was founded in 2013 and is based in Durham, North Carolina.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.